Developing Strong Medical Information Groups: Collaboration and Challenges

Non-members: Click here to review a complimentary excerpt from “Developing Strong Medical Information Groups: Collaboration and Challenges”

STUDY OVERVIEW

Medical information groups play a vital role in providing product information and tracking product problems. Thus, it is important for these groups to collaborate effectively with internal groups to ensure the right information is conveyed to key stakeholders and to share important information with other internal groups such as drug safety.

Best Practices, LLC conducted this study to identify critical requirements for a robust and effective medical information group. In particular, this study identifies efficient ways for internal collaboration, requisite capabilities and challenges encountered by the function.

KEY TOPICS

• Collaboration with Legal Department and Other Internal Groups
• Challenges Faced by Medical Information Groups
• Important Capabilities for Medical Information Groups

KEY METRICS

• Legal Department's Role in Reviewing Medical Information Letters
• Medical Information Groups’ Internal Collaboration Scores
• Importance of Partnerships with Different Functions for the Medical Information Group
• Challenges faced by the Medical Information Group
• Important Capabilities for Medical Information Groups

SAMPLE KEY FINDINGS

• Collaboration with Legal Groups: To avoid compliance issues, it’s critical for medical information to collaborate with legal groups. For instance 46% of the participants have all of their medical information letters reviewed by their companies’ legal groups.
• Internal Collaboration: The top two groups that Medical Information collaborates with are: Medical Science Liaison teams and Pharmacovigilance departments.

METHODOLOGY

Best Practices, LLC engaged 26 executives from 25 leading biopharmaceutical companies for this benchmarking study. Eleven participants represent large biopharmaceutical organizations, while 8 participants represent medium-sized companies and the remaining participants represent small companies. Also 8 companies form a US-only segment, while 19 companies form a Global segment.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care


Companies Profiled:
Abbvie; Alnylam Pharmaceuticals; Astellas; AstraZeneca; Baxalta; Bayer; Boehringer Ingelheim; CSL Behring; Ferring Pharmaceuticals; Galderma; GW Pharmaceuticals; Incyte; Janssen; Lundbeck; Merck; Novartis; Neurocrine Biosciences; Pierre Fabre Medicament; ProStrakan; Pfizer; Sunovion; Teva Pharmaceutical Industries Ltd; Tillotts Pharma; Upsher-Smith; Xenoport

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.